Nearly 2,000 more hospitals can buy Beyond Air's tankless nitric oxide system Effective April 1, the deal opens access across nearly 2,000 U.S. hospitals and systems, giving providers a simpler path to evaluate LungFit PH.

#XAIR Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

www.stocktitan.net/news/XAIR/beyond-air-exp...

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial Beyond Cancer (NASDAQ: XAIR) reported interim Phase 1 UNO data showing early clinical activity and a favorable safety profile after a single intratumoral injection in ten heavily pretreated patients with cutaneous or subcutaneous tumors.Key points: two triple negative breast cancer patients show no evidence of disease, seven patients alive 19–37 months post‑treatment, most adverse events Grade 1, one treatment‑related serious hypoxia event that resolved.

#XAIR Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

www.stocktitan.net/news/XAIR/beyond-cancer-...

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. Beyond Air (NASDAQ: XAIR) announced that the previously disclosed proposed sale of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd. will not proceed. A January 2026 letter of intent expired on March 9, 2026 and the parties did not execute a definitive agreement.The company said it will retain its interest in NeuroNOS, continue to evaluate strategic alternatives for the NeuroNOS platform, and remain focused on advancing its core nitric oxide platform and LungFit programs.

#XAIR Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

www.stocktitan.net/news/XAIR/beyond-air-ann...

Fundamental analysis of $XAIR (Beyond Air, Inc.) based on financial data and reported results.

#XAIR